Cyclacel Pharmaceuticals (CYCC) Competitors $16.04 -1.11 (-6.47%) Closing price 04:00 PM EasternExtended Trading$16.06 +0.02 (+0.09%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCC vs. RLMD, RVPH, FNCH, VYNE, CING, BLRX, MEIP, AYTU, HOTH, and CARMShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include Relmada Therapeutics (RLMD), Reviva Pharmaceuticals (RVPH), Finch Therapeutics Group (FNCH), VYNE Therapeutics (VYNE), Cingulate (CING), BioLineRx (BLRX), MEI Pharma (MEIP), Aytu BioPharma (AYTU), Hoth Therapeutics (HOTH), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical products" industry. Cyclacel Pharmaceuticals vs. Its Competitors Relmada Therapeutics Reviva Pharmaceuticals Finch Therapeutics Group VYNE Therapeutics Cingulate BioLineRx MEI Pharma Aytu BioPharma Hoth Therapeutics Carisma Therapeutics Relmada Therapeutics (NASDAQ:RLMD) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends. Which has more volatility & risk, RLMD or CYCC? Relmada Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Which has stronger valuation & earnings, RLMD or CYCC? Cyclacel Pharmaceuticals has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$79.98M-$2.51-0.26Cyclacel Pharmaceuticals$40K633.58-$11.21M-$839.58-0.02 Does the media favor RLMD or CYCC? In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 2 mentions for Cyclacel Pharmaceuticals and 1 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.89 beat Cyclacel Pharmaceuticals' score of 0.30 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Relmada Therapeutics Very Positive Cyclacel Pharmaceuticals Neutral Do analysts rate RLMD or CYCC? Relmada Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 673.16%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Relmada Therapeutics is more favorable than Cyclacel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is RLMD or CYCC more profitable? Relmada Therapeutics' return on equity of -181.26% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -181.26% -151.23% Cyclacel Pharmaceuticals N/A -3,648.09%-155.99% Do insiders and institutionals hold more shares of RLMD or CYCC? 45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 20.7% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 51.2% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryRelmada Therapeutics beats Cyclacel Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCC vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.34M$3.04B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-0.0221.1828.1120.03Price / Sales633.58339.43461.37103.88Price / CashN/A43.2336.5559.01Price / Book-0.278.368.655.90Net Income-$11.21M-$55.19M$3.25B$258.66M7 Day Performance22.72%5.89%4.20%2.23%1 Month Performance192.57%17.63%10.82%12.76%1 Year Performance-96.02%5.09%34.70%19.36% Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCCyclacel Pharmaceuticals1.1004 of 5 stars$16.04-6.5%N/A-95.8%$25.34M$40K-0.0214Gap DownRLMDRelmada Therapeutics4.8118 of 5 stars$0.63+2.9%$5.00+696.8%-83.6%$20.83MN/A-0.2510Positive NewsGap DownRVPHReviva Pharmaceuticals3.3911 of 5 stars$0.43+9.7%$9.00+1,996.4%-63.4%$20.61MN/A-0.545Positive NewsGap UpHigh Trading VolumeFNCHFinch Therapeutics GroupN/A$12.75flatN/A+657.6%$20.48MN/A-1.45190VYNEVYNE Therapeutics2.9571 of 5 stars$1.33-6.3%$6.25+369.9%-33.0%$20.23M$500K-1.3430Positive NewsHigh Trading VolumeCINGCingulate3.2576 of 5 stars$4.73+8.7%$26.00+449.7%+1,352.1%$20.08MN/A-0.5620News CoveragePositive NewsBLRXBioLineRx2.8139 of 5 stars$4.70flat$26.00+453.2%-86.3%$20.04M$22.34M-0.5340Positive NewsMEIPMEI Pharma1.6599 of 5 stars$2.94+9.3%N/A+99.4%$19.58MN/A-0.62100News CoveragePositive NewsHigh Trading VolumeAYTUAytu BioPharma4.135 of 5 stars$2.15-1.4%$10.00+365.1%-3.6%$19.31M$81M-2.99160HOTHHoth Therapeutics2.9632 of 5 stars$1.43-0.7%$4.00+179.7%+21.5%$18.89MN/A-1.254Analyst ForecastCARMCarisma Therapeutics3.1687 of 5 stars$0.45+12.7%$1.93+327.0%-63.5%$18.84M$19.63M-0.2920Positive News Related Companies and Tools Related Companies Relmada Therapeutics Competitors Reviva Pharmaceuticals Competitors Finch Therapeutics Group Competitors VYNE Therapeutics Competitors Cingulate Competitors BioLineRx Competitors MEI Pharma Competitors Aytu BioPharma Competitors Hoth Therapeutics Competitors Carisma Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCC) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
